A commentary in Nature Medicine proposes a unified approach to genome screening, data integration and early disease prevention for the Arab Gulf states.[1] States in this area need a common genomic health strategy due to the high incidence of disease and the lack of representative genetic data.[1][2] The Qatar Genome Program (QGP) has already sequenced the genomes of 25,000 Qataris and plans to reach 100,000 by 2025, with the aim of introducing precision medicine.[2] Research has shown that 99.5% of individuals studied have at least one clinically significant genetic variant affecting drug safety and efficacy.[1] A pan-Arab genotyping array of approximately 800,000 variants is proposed for the study of diabetes, cardiovascular and metabolic diseases, autism, hereditary disorders, and cancer.[2] Collaboration is essential for the region's small populations and ethnic diversity to achieve effective prevention and personalized treatment.[3] These strategies have the potential to save thousands to hundreds of thousands of dollars through national screening programs.[3]